Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BioFlow

Financiado

The development of a predictive biomarker for immunotherapy outcome based on flo...

The development of a predictive biomarker for immunotherapy outcome based on flow cytometry test Immunotherapy has revolutionised clinical oncology, with the use of immune checkpoint inhibitors (ICIs). These agents are in clinical use for almost a decade, treating over 20 types of cancers. They have shown a remarkable therape... ver más

29/02/2024

TECHNION ISRAEL I...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

TECHNION ISRAEL INSTITUTE OF TECHNOLOGY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-29

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2 Objective:Objectives:

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

TECHNION ISRAEL INSTITUTE O...

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CPP2021-008390 Cuantificación en paralelo de múltiples interacciones de pun... 225K€ Cerrado

EUIN2017-87932 IDENTIFICACION DE BIOMARCADORES DE RESPUESTA A INMUNOTERAPIA... 10K€ Cerrado

IOO - Improving IO IOO: a novel assay to predict patient response to immune che... 4M€ Cerrado

SAF2017-84091-R LINFOCITOS TRANSFAGOCITICOS COMO SIGUIENTE GENERACION DE INM... 218K€ Cerrado

FJC2018-035449-I Cancer Immunology and Immunotherapy 50K€ Cerrado

SAF2017-83732-R REPROGRAMACION DEL MICROAMBIENTE TUMORAL PARA AUMENTAR LA EF... 339K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2022-08-01
Fecha Fin: 2024-02-29

Líder del proyecto

TECHNION ISRAEL INSTITUTE OF TECHNOLOGY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Immunotherapy has revolutionised clinical oncology, with the use of immune checkpoint inhibitors (ICIs). These agents are in clinical use for almost a decade, treating over 20 types of cancers. They have shown a remarkable therapeutic benefit even in patients with advanced disease. Yet, only a small proportion of patients benefit from this therapy, leaving the rest resistant, for reasons that are still not clear. While there are certain clinical biomarkers to predict ICI therapy outcome, their prevalence and prediction power is rather limited. Therefore, there is a clinical unmet need to develop more powerful biomarkers to predict response to immunotherapy. In our ongoing ERC consolidator grant we discovered a unique sub-population of neutrophils, present in peripheral blood, that predicts response to immunotherapy in a very high probability. We designated these cells as immunotherapy-responsiveness cells (IRCs). Using various mouse models, we demonstrate that the levels of circulating IRCs measured at baseline are significantly higher in responding tumours to ICI therapy. These results were confirmed in a limited number of non-small cell lung cancer (NSCLC) and melanoma patients. Hence, our aim is to further test IRC levels in clinical samples, to evaluate their predictive power for ICI therapy, and to develop a clinical liquid biopsy-based predictive biomarker using flow cytometry test. The development of clinical IRC detection based on flow cytometry (BioFlow®) can serve two markets: (1) Clinicians – enabling oncologists to easily predict response to ICI therapy, thus improving personalised immunotherapy treatment; and (2) Pharmaceutical companies - developing immunotherapies - that can use IRC detection in development stages and through clinical studies, enabling tight regulative assessment of R&D success rates. The BioFlow goal is to technically validate and develop a predictive biomarker platform for both markets that will lead to its commercialisation.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores